Vedolizumab as a successful treatment of CTLA-4–associated autoimmune enterocolitis - 19/04/17
Doi : 10.1016/j.jaci.2016.08.042
Alexander A. Navarini, MD, PhD a, ∗, Petr Hruz, MD, PhD b, ∗, Christoph T. Berger, MD c, ∗, Tie Zheng Hou, MD, PhD d, ∗, Charlotte Schwab e, ∗, Annemarie Gabrysch e, ∗, Rebecca Higgins, MSc a, Natalie Frede, MSc e, Barbara-Christina Padberg Sgier, MD f, Olle Kämpe, PhD g, h, Anne-Valérie Burgener, MD i, Florian Marquardsen, MSc j, Fabian Baldin, MSc j, Marc Bigler, MSc c, Anne Kistner, MSc c, Annaise Jauch, MD j, Olivier Bignucolo, PhD k, Benedikt Meyer, MSc j, Fabian Meienberg, MD l, Matthias Mehling, MD m, Lukas T. Jeker, MD, PhD n, Ingmar Heijnen, PhD o, Thomas D. Daikeler, MD p, Jan-Olaf Gebbers, MD f, Bodo Grimbacher, MD e, ‡, David M. Sansom, PhD d, ‡, Raphael Jeker, MD q, ‡, Christoph Hess, MD, PhD i, ‡, Mike Recher, MD j, ‡ 
a Department of Dermatology, University Hospital, Zurich, Switzerland
b Gastroenterology, University Hospital, Basel, Switzerland
c Translational Immunology, Department of Biomedicine, University Hospital, Basel, Switzerland
d Institute of Immunity and Transplantation, University College London, Royal Free Campus, London, United Kingdom
e Center for Chronic Immunodeficiency, Medical Center–Faculty of Medicine, University of Freiburg, Freiburg, Germany
f Institute of Pathology, Cantonal Hospital Graubünden, Chur, Switzerland
g Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden
h Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
i Immunobiology Lab, Department of Biomedicine, University Hospital, Basel, Switzerland
j Immunodeficiency Lab, Department of Biomedicine, University Hospital, Basel, Switzerland
k SIB Swiss Institute of Bioinformatics and Biozentrum, University of Basel, Basel, Switzerland
l Endocrinology, University Hospital, Basel, Switzerland
m Translational Neuroimmunology, Department of Biomedicine, University Hospital, Basel, Switzerland
n Molecular Immune Regulation, Department of Biomedicine, University Hospital, Basel, Switzerland
o Division of Medical Immunology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland
p Rheumatology, University Hospital, Basel, Switzerland
q Department of Internal Medicine, Kantonsspital Graubünden, Chur, Switzerland
| This work was supported by Swiss National Science Foundation grants to M.R. (grant no. PP00P3_144863) and C.T.B. (grant no. PZ00P3_148000). M.R. and C.H. were supported by the Gebert Rüf foundation (grant no. GRS-058/14). This work was supported in part by the BMBF grants 01E01303 and 01ZX1306F to B.G. |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Tous droits réservés.
Vol 139 - N° 3
P. 1043 - mars 2017 Retour au numéro
Article précédent
- Outcome of patients with NEMO deficiency following allogeneic hematopoietic cell transplant
- Shanmuganathan Chandrakasan, Rebecca A. Marsh, Gulbu Uzel, Steven M. Holland, Kara N. Shah, Jack Bleesing
- Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome
- Zohreh Nademi, Mary A. Slatter, Christopher C. Dvorak, Benedicte Neven, Alain Fischer, Felipe Suarez, Claire Booth, Kanchan Rao, Alexandra Laberko, Julia Rodina, Yves Bertrand, Sylwia Ko?tan, Robert D?bski, Terence Flood, Mario Abinun, Andrew R. Gennery, Sophie Hambleton, Stephan Ehl, Andrew J. Cant
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?